Alembic Pharma Q2: US Generics Revenue Jumps 77%, FY27 Growth Guidance Raised | Business News
ET Now · 05 Nov 2026 · 6 min
Management interview of Alembic Pharmaceuticals Ltd (APLLTD), with 9 key numbers discussed.
- Pranav Amin, Managing Director, Alembic Pharmaceuticals
Alembic Pharmaceuticals reported strong Q2 performance driven by a 77% surge in US generics revenue, with base business growing 23%. Management raised FY27 full-year US generics growth guidance to 40% and consolidated revenue growth target to 20-25%. Exclusivity for Bosutinib expires at November-end, but 30 US launches are planned over 18 months to sustain growth. India business grew 14% supported by structural changes and specialty chronic segment outperformance. US branded business will dilute FY27 margins by 150 bps before breaking even in H1FY28.